Gil Alfonso Magos-Guerrero

Dr. Gil Alfonso Magos-Guerrero

Departamento de Farmacología, Facultad de Medicina, UNAM

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 January 2014 in Nutrients
Verified
Journal Article
Open access
PDF file
HMHector Merino-Aguilar
Hector Merino-Aguilar
DADaniel Arrieta-Baez
Daniel Arrieta-Baez
MJManuel Jimenez-Estrada
Manuel Jimenez-Estrada
Gil Alfonso Magos-GuerreroGil Alfonso Magos-Guerrero
Gil Alfonso Magos-Guerrero
RBRené Javier Hernández Bautista
René Javier Hernández Bautista
FAFrancisco Alarcon Aguilar
Francisco Alarcon Aguilar
Psacalium decompositum, commonly known as “Matarique,” is a medicinal plant used in Mexico for diabetes mellitus empirical therapy. Previous studies have shown that the fructooligosaccharides (FOS) present in the roots of this plant exhibit a notable hypoglycemic effect in animal models; this effect might be associated with the attenuation of the inflammatory process and other metabolic disorders. In this study, we examined the effects of FOS fraction administration in a fructose-fed rat model for obesity. Phytochemical chromatographic studies (high performance thin layer chromatography and nuclear magnetic resonance) were performed to verify isolation of FOS. 24 male Wistar rats were maintained for 12 weeks on a diet of 20% HFCS in drinking water and chow. Glucose, cholesterol, triglycerides and liver transaminases levels were measured monthly, after administering FOS fraction intragastrically (150 mg/kg/day for 12 weeks), while the levels of inflammatory cytokines were only quantified at the end of the treatments. Rats treated with FOS fraction decreased body weight, cholesterol, triglycerides, and significantly reduced IL-6, IFN-γ, MCP-1, IL-1β and VEGF levels (p < 0.05). These results suggest that P. decompositum has anti-inflammatory and hypolipidemic properties that might be used as an alternative treatment for the control of obesity.

22 March 2021 in Biomolecules
Verified
Journal Article
Open access
PDF file
Oscar Salvador Barrera-VázquezOscar Salvador Barrera-Vázquez
Oscar Salvador Barrera-Vázquez
CVCarlos Verjan
Carlos Verjan
Gil Alfonso Magos-GuerreroGil Alfonso Magos-Guerrero
Gil Alfonso Magos-Guerrero
Cellular senescence is a cellular condition that involves significant changes in gene expression and the arrest of cell proliferation. Recently, it has been suggested in experimental models that the elimination of senescent cells with pharmacological methods delays, prevents, and improves multiple adverse outcomes related to age. In this sense, the so-called senoylitic compounds are a class of drugs that selectively eliminates senescent cells (SCs) and that could be used in order to delay such adverse outcomes. Interestingly, the first senolytic drug (navitoclax) was discovered by using chemoinformatic and network analyses. Thus, in the present study, we searched for novel senolytic compounds through the use of chemoinformatic tools (fingerprinting and network pharmacology) over different chemical databases (InflamNat and BIOFACQUIM) coming from natural products (NPs) that have proven to be quite remarkable for drug development. As a result of screening, we obtained three molecules (hinokitiol, preussomerin C, and tanshinone I) that could be considered senolytic compound candidates since they share similarities in structure with senolytic leads (tunicamycin, ginsenoside Rb1, ABT 737, rapamycin, navitoclax, timosaponin A-III, digoxin, roxithromycin, and azithromycin) and targets involved in senescence pathways with potential use in the treatment of age-related diseases.

20 November 2023 in Biomolecules
Verified
Journal Article
Open access
PDF file
Oscar Salvador Barrera-VázquezOscar Salvador Barrera-Vázquez
Oscar Salvador Barrera-Vázquez
SMSergio Montenegro
Sergio Montenegro
MEMaría Elena Martínez Enríquez
María Elena Martínez Enríquez
JEJuan Luis Escobar-Ramírez
Juan Luis Escobar-Ramírez
Gil Alfonso Magos-GuerreroGil Alfonso Magos-Guerrero
Gil Alfonso Magos-Guerrero
Many natural products have been acquired from plants for their helpful properties. Medicinal plants are used for treating a variety of pathologies or symptoms. The axes of many pathological processes are inflammation, oxidative stress, and senescence. This work is focused on identifying Mexican medicinal plants with potential anti-oxidant, anti-inflammatory, anti-aging, and anti-senescence effects through network analysis and chemoinformatic screening of their phytochemicals. We used computational methods to analyze drug-like phytochemicals in Mexican medicinal plants, multi-target compounds, and signaling pathways related to anti-oxidant, anti-inflammatory, anti-aging, and anti-senescence mechanisms. A total of 1373 phytochemicals are found in 1025 Mexican medicinal plants, and 148 compounds showed no harmful functionalities. These compounds displayed comparable structures with reference molecules. Based on their capacity to interact with pharmacological targets, three clusters of Mexican medicinal plants have been established. Curatella americana, Ximenia americana, Malvastrum coromandelianum, and Manilkara zapota all have anti-oxidant, anti-inflammatory, anti-aging, and anti-senescence effects. Plumeria rubra, Lonchocarpus yucatanensis, and Salvia polystachya contained phytochemicals with anti-oxidant, anti-inflammatory, anti-aging, and anti-senescence reported activity. Lonchocarpus guatemalensis, Vallesia glabra, Erythrina oaxacana, and Erythrina sousae have drug-like phytochemicals with potential anti-oxidant, anti-inflammatory, anti-aging, and anti-senescence effects. Between the drug-like phytochemicals, lonchocarpin, vallesine, and erysotrine exhibit potential anti-oxidant, anti-inflammatory, anti-aging, and anti-senescence effects. For the first time, we conducted an initial virtual screening of selected Mexican medicinal plants, which was subsequently confirmed in vivo, evaluating the anti-inflammatory activity of Lonchocarpus guatemalensis Benth in mice.

22 November 2023 in Molecules
Verified
Journal Article
Open access
PDF file
JEJuan Luis Escobar-Ramírez
Juan Luis Escobar-Ramírez
JSJacinto Santiago-Mejía
Jacinto Santiago-Mejía
MNMaribel Soto Nuñez
Maribel Soto Nuñez
Oscar Salvador Barrera-VázquezOscar Salvador Barrera-Vázquez
Oscar Salvador Barrera-Vázquez
RVRoberto Vargas-Querea
Roberto Vargas-Querea
Gil Alfonso Magos-GuerreroGil Alfonso Magos-Guerrero
Gil Alfonso Magos-Guerrero
Chiranthodendron pentadactylon Larreat is a tree native to southeastern Mexico and Guatemala. Its flower is used in Mexican folk medicine to treat a variety of diseases, including conditions of blood pressure. However, scientific information on its usefulness in this pathology is lacking. The present study evaluates the effect of a methanolic extract (ME) from the flower and its active constituents on heart rate (HR) and mean arterial pressure (MAP) in anesthetized rats (MAPHR). The study also analyzed the effects on rat-isolated aortic rings (RIAR) and the rat mesenteric arterial bed (MABR). Active fractions were chromatographed, which led to the isolation of cyanidin 3-O-glucoside (C3G) identified through HPLC. The Chiranthodendron pentadactylon flowers produced hypotensive and vasorelaxant effects associated with C3G. The vasorelaxant effect is a mechanism underlying the synthesis and release of nitric oxide (NO). Neither cholinergic receptors nor prostaglandins are involved. ME and C3G cause cardiovascular depression in anesthetized rats via cholinergic and prostanoid mechanisms. Our research expands the scientific understanding of the flowers on the rat cardiovascular system. This amplifies the appreciation of the flower’s ethnomedicine employed to control blood pressure. However, researchers need to conduct toxicity studies to determine the safety of this plant.

5 December 2023 in Molecules
Verified
Journal Article
Open access
PDF file
Oscar Salvador Barrera-VázquezOscar Salvador Barrera-Vázquez
Oscar Salvador Barrera-Vázquez
JEJuan Luis Escobar-Ramírez
Juan Luis Escobar-Ramírez
JSJacinto Santiago-Mejía
Jacinto Santiago-Mejía
OCOmar Francisco Carrasco-Ortega
Omar Francisco Carrasco-Ortega
Gil Alfonso Magos-GuerreroGil Alfonso Magos-Guerrero
Gil Alfonso Magos-Guerrero
Peripheral venous hypertension has emerged as a prominent characteristic of venous disease (VD). This disease causes lower limb edema due to impaired blood transport in the veins. The phlebotonic drugs in use showed moderate evidence for reducing edema slightly in the lower legs and little or no difference in the quality of life. To enhance the probability of favorable experimental results, a virtual screening procedure was employed to identify molecules with potential therapeutic activity in VD. Compounds obtained from multiple databases, namely AC Discovery, NuBBE, BIOFACQUIM, and InflamNat, were compared with reference compounds. The examination of structural similarity, targets, and signaling pathways in venous diseases allows for the identification of compounds with potential usefulness in VD. The computational tools employed were rcdk and chemminer from R-Studio and Cytoscape. An extended fingerprint analysis allowed us to obtain 1846 from 41,655 compounds compiled. Only 229 compounds showed pharmacological targets in the PubChem server, of which 84 molecules interacted with the VD network. Because of their descriptors and multi-target capacity, only 18 molecules of 84 were identified as potential candidates for experimental evaluation. We opted to evaluate the berberine compound because of its affordability, and extensive literature support. The experiment showed the proposed activity in an acute venous hypertension model.

Verified
Journal Article
Open access
PDF file
DSDavid Segura-Cobos
David Segura-Cobos
ESEsperanza Enedina Díaz Salgado
Esperanza Enedina Díaz Salgado
DADante Amato
Dante Amato
SGSINAI ERNESTO CARDOSO GARCIA
SINAI ERNESTO CARDOSO GARCIA
TOMAS VILLAMAR-DUQUETOMAS VILLAMAR-DUQUE
TOMAS VILLAMAR-DUQUE
EHElizabeth Alejandrina Guzmán Hernández
Elizabeth Alejandrina Guzmán Hernández
Diabetic nephropathy (DN) is a serious complication of diabetes mellitus; oxidative stress plays a key role in the pathogenesis of DN. The objective of this study was to evaluate the antioxidant effect of vitamin E on diabetic nephropathy. A control group and three groups of rats with streptozotocin-induced diabetes mellitus (untreated diabetic rats and diabetic rats treated with vitamin E 250 and 500 mg/kg) were studied. After 4 weeks of treatment, the kidneys were removed under anesthesia with sodium pentobarbital. The kidneys were weighed, the AT1 and AT2 receptor expression was measured by Western blot, and the activities of glutathione peroxidase, catalase, and superoxide dismutase were determined in the renal cortex. Rats with diabetes mellitus had hyperglycemia, increased food and water consumption, and higher urinary volume than control rats. In diabetic rats (DM), kidney hypertrophy was observed and measured by kidney weight, protein/DNA ratio in the renal cortex, and proximal tubular cell area; proteinuria and reduced creatinine clearance were observed. AT1 and AT2 receptor expression in the kidney cortex of DM rats increased significantly compared to normoglycemic rats; antioxidant enzyme activities were decreased; treatment with vitamin E reversed kidney hypertrophy and reduced proteinuria; reduction in expression of AT1 and AT2 receptors was associated with increased antioxidant activity. Thus, treatment with vitamin E slows the progress of DN.